Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Another Step Towards Myeloma Market Dominance For Amgen's Kyprolis

This article was originally published in Scrip

Executive Summary

Amgen Inc.'s Kyprolis (carfilzomib) has been given the green light in Europe for the treatment of relapsed multiple myeloma, after being pushed through reviews under the European Medicines Agency's accelerated assessment program.


Related Content

Amgen's Kyprolis Miss In First-Line Myeloma Surprising, But Clinically Irrelevant


Related Companies